A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer
A Randomized, Open-label Study of the Effect of Adjuvant Therapy With Adriamycin Plus Cytoxan Followed by Taxotere or Taxotere Plus Xeloda on Overall Survival in Female Patients With High-risk Breast Cancer
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Texas
-
Houston, Texas, Forenede Stater, 77060
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- female patients 18-70 years of age;
- adenocarcinoma of the breast;
- previous invasive breast cancer if diagnosed >5 years before entering study;
- no evidence of metastatic disease.
Exclusion Criteria:
- history of severe hypersensitivity reaction to Taxotere;
- previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane;
- treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: 1
|
825mg/m2 po bud på dag 1-14 i hver 3 ugers cyklus
75 mg/m2 iv på dag 1 i hver 3-ugers cyklus
100mg/m2 iv on day 1 of each 3 week cycle
|
|
Aktiv komparator: 2
|
75 mg/m2 iv på dag 1 i hver 3-ugers cyklus
100mg/m2 iv on day 1 of each 3 week cycle
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Disease Free Survival [Number of Events]
Tidsramme: Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.
|
Number of patients with/without recurrence of breast cancer, or death due to any cause.
|
Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.
|
|
Disease Free Survival [Time to Event]
Tidsramme: Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.
|
Disease free survival was measured as the time from the date of randomization until the date of first event (recurrence of breast cancer, or death due to any cause).
Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.
|
Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival [Number of Events]
Tidsramme: Time from the date of randomization to the date of death, or date last known to be alive. Patients were followed for an average of 5 years.
|
Number of patients who died/were alive.
|
Time from the date of randomization to the date of death, or date last known to be alive. Patients were followed for an average of 5 years.
|
|
Overall Survival [Time to Event]
Tidsramme: Time from the date of randomization to the date of death, or date last known to be alive. Patients were followed for an average of 5 years.
|
Overall survival was measured as the time from the date of randomization to the date of death.
Patients still alive at the time of the analysis were censored using the date they were last known to be alive.
|
Time from the date of randomization to the date of death, or date last known to be alive. Patients were followed for an average of 5 years.
|
|
Breast Cancer Free Survival [Number of Events]
Tidsramme: Time from the date of randomization to event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years .
|
Number of patients with/without recurrence of breast cancer, new primary breast cancer, or death related to the chemotherapy administered or due to breast cancer.
|
Time from the date of randomization to event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years .
|
|
Breast Cancer Free Survival [Time to Event]
Tidsramme: Time from the date of randomization to death, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.
|
Breast cancer-free survival was measured as time from the date of randomization to the date of recurrence of breast cancer, new primary breast cancer, or death related to the chemotherapy administered or due to breast cancer.
Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.
|
Time from the date of randomization to death, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.
|
|
Disease Free Survival Including New Primary Breast Cancer as Event [Number of Events]
Tidsramme: Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.
|
Number of patients with/without recurrence of breast cancer, new primary breast cancer, or death due to any cause.
|
Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.
|
|
Disease Free Survival Including New Primary Breast Cancer as Event [Time to Event
Tidsramme: Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.
|
Time from the date of randomization until the date of first event (recurrence of breast cancer, new primary breast cancer, or death due to any cause).
Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.
|
Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.
|
|
Disease Free Survival Including Any New Cancer as Event [Number of Events]
Tidsramme: Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.
|
Number of patients with/without recurrence of breast cancer, any new cancer, or death due to any cause.
|
Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.
|
|
Disease Free Survival Including Any New Cancer as Event [Time to Event]
Tidsramme: Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.
|
Time from the date of randomization until the date of first event (recurrence of breast cancer, any new cancer, or death due to any cause).
Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.
|
Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NO17629
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .